Apheresis Collection for New Drug Development and Evaluation Research
ConditionPBMCs
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-40
SponsorTCRx Therapeutics Co.Ltd
About this trial
Peripheral Blood Mononuclear Cells (PBMC) are a mixed population of cells with a single nucleus found in peripheral blood (i.e., blood outside the bone marrow), including natural killer cells (NK), T lymphocytes (70% - 90%), and B lymphocytes. They can be further isolated and purified and are the main source of immune cells. This study will be conducted at our hospital, with a planned recruitment of 200 subjects. Subjects who meet the inclusion criteria and do not meet the exclusion criteria will have their peripheral blood mononuclear cells collected via apheresis. Each subject will need to provide an apheresis sample containing approximately 8×10\^9 mononuclear cells (with a sample volume of about 150 mL).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Aged between 18 and 40 (inclusive), male or non-pregnant female, regardless of nationality.
Disqualifiers
Previously had adverse reactions to blood donation. The following diseases are considered clinically significant by researchers: autoimmune diseases, severe endocrine and metabolic diseases, malignant tumors, neuropsychiatric diseases; Creutzfeldt-Jakob disease and those with a family history, or those who have received treatment with tissues or tissue derivatives that may have been infected with the Creutzfeldt-Jakob pathogen; chronic skin diseases, especially infectious, allergic, or inflammatory systemic skin diseases; those with allergic diseases or recurrent allergies; those who have undergone surgical operations in the past three months.
Trial population
healthy individuals
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
None AHT
Other interventionNo intervention measures
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: DCX-0011 intervention
Trial outcomes
Primary outcomes
1
Research on the in vitro isolation, cell expansion, and function of mononuclear cells;
Time frame
Baseline and 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov